vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $16.5M, roughly 1.2× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -84.4%, a 59.5% gap on every dollar of revenue.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
FVR vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $20.6M |
| Net Profit | $-4.1M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | — | -106.0% |
| Net Margin | -24.9% | -84.4% |
| Revenue YoY | — | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $-0.19 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $16.2M | $20.6M | ||
| Q4 24 | — | $37.4M | ||
| Q3 24 | $14.5M | $19.6M | ||
| Q2 24 | — | $94.7M | ||
| Q1 24 | — | $59.1M |
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-833.0K | $-17.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $-2.4M | $-14.0M | ||
| Q2 24 | — | $55.0M | ||
| Q1 24 | — | $23.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | 35.7% |
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | — | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -5.1% | -84.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -16.7% | -71.7% | ||
| Q2 24 | — | 58.1% | ||
| Q1 24 | — | 39.7% |
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.06 | $-0.42 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $1.55 | ||
| Q1 24 | — | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $67.8M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $417.3M |
| Total Assets | $854.4M | $486.5M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $3.3M | $67.8M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | — | ||
| Q2 25 | $369.9M | — | ||
| Q1 25 | $324.7M | $417.3M | ||
| Q4 24 | — | $428.7M | ||
| Q3 24 | $1.0K | $422.4M | ||
| Q2 24 | — | $429.9M | ||
| Q1 24 | — | $269.4M |
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | — | ||
| Q2 25 | $856.5M | — | ||
| Q1 25 | $860.8M | $486.5M | ||
| Q4 24 | — | $526.3M | ||
| Q3 24 | $1.0K | $554.6M | ||
| Q2 24 | — | $582.0M | ||
| Q1 24 | — | $510.8M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | $-38.5M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | — | $-24.3M | ||
| Q2 24 | — | $39.8M | ||
| Q1 24 | — | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
